Translational pediatrics · 2026
Epidemic features and clinical analysis of pediatric Mycoplasma pneumoniae respiratory infection before, during, and after COVID-19 pandemic: a 7-year study in southern China.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Aiping, He Qiaoqiao, Xiao Zhigang, Wu Yiqiu, Zhong Huan, Lu Gen, Fan Huifeng
Аннотация
BACKGROUND: In the period spanning 2023 to 2024, there was a global resurgence of Mycoplasma pneumoniae (M. pneumoniae) infections following the coronavirus disease 2019 (COVID-19) pandemic. This 7-year retrospective study investigated the epidemic features and clinical severity of pediatric M. pneumoniae respiratory infection in southern China across the pre-, during, and post-COVID-19 periods.
METHODS: A retrospective analysis was conducted on the clinical data of patients aged 0-18 years who visited Meizhou Maternal and Children's Health Hospital from January 1, 2018 to September 30, 2024, with a serum M. pneumoniae immunoglobulin M (IgM) ≥1:160 and/or a positive M. pneumoniae polymerase chain reaction (PCR) test.
RESULTS: Of 76,859 tested children, 19,884 were M. pneumoniae positive (overall positive rate 25.9%). The post-COVID-19 period exhibited significantly higher M. pneumoniae positive rate (41.0%), median age of onset, and hospitalization rate compared with the pre- and during-COVID-19 periods (all P<0.001). Among hospitalized patients, post-COVID-19 refractory Mycoplasma pneumoniae pneumonia (RMPP) incidence was markedly elevated (P<0.05), accompanied by higher M. pneumoniae-DNA load, increased pleural effusion complications, and elevated co-infection rates (all P<0.05). For RMPP patients, post-COVID-19 cohorts had a higher proportion of children >6 years and higher respiratory distress incidence (P<0.05), with lower lobar pneumonia/atelectasis rates and reduced macrolide effectiveness (P<0.001). No significant differences in severe Mycoplasma pneumoniae pneumonia (SMPP) incidence, hospital stay duration, or mortality were observed across the three periods (P>0.05).
CONCLUSIONS: Post-COVID-19 pediatric M. pneumoniae respiratory infection in southern China featured higher incidence, longer epidemic duration, and a marked rise in RMPP, with no concomitant increase in SMPP.
METHODS: A retrospective analysis was conducted on the clinical data of patients aged 0-18 years who visited Meizhou Maternal and Children's Health Hospital from January 1, 2018 to September 30, 2024, with a serum M. pneumoniae immunoglobulin M (IgM) ≥1:160 and/or a positive M. pneumoniae polymerase chain reaction (PCR) test.
RESULTS: Of 76,859 tested children, 19,884 were M. pneumoniae positive (overall positive rate 25.9%). The post-COVID-19 period exhibited significantly higher M. pneumoniae positive rate (41.0%), median age of onset, and hospitalization rate compared with the pre- and during-COVID-19 periods (all P<0.001). Among hospitalized patients, post-COVID-19 refractory Mycoplasma pneumoniae pneumonia (RMPP) incidence was markedly elevated (P<0.05), accompanied by higher M. pneumoniae-DNA load, increased pleural effusion complications, and elevated co-infection rates (all P<0.05). For RMPP patients, post-COVID-19 cohorts had a higher proportion of children >6 years and higher respiratory distress incidence (P<0.05), with lower lobar pneumonia/atelectasis rates and reduced macrolide effectiveness (P<0.001). No significant differences in severe Mycoplasma pneumoniae pneumonia (SMPP) incidence, hospital stay duration, or mortality were observed across the three periods (P>0.05).
CONCLUSIONS: Post-COVID-19 pediatric M. pneumoniae respiratory infection in southern China featured higher incidence, longer epidemic duration, and a marked rise in RMPP, with no concomitant increase in SMPP.